{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:35:38Z","timestamp":1788968138111,"version":"build-2803163510"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"suppl_1","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Background: The recommendation that antibiotics should be used for routine therapy of travellers\u2019 diarrhoea is being reconsidered in view of growing evidence that the therapy may lead to intestinal carriage of multi-drug resistant (MDR) colonic microbiota. This review attempts to put the issues of therapy and MDR acquisition in perspective to help in the establishment of therapeutic recommendations for travellers\u2019 diarrhoea.<\/jats:p><jats:p>Methods: The existing literature showing the risk and consequences of acquisition of MDR microbiota in antibiotic-treated travellers was reviewed. Issues important to the development of firm evidence-based recommendations for antibiotics use for treatment and prevention of travellers\u2019 diarrhoea were researched.<\/jats:p><jats:p>Results: Six areas of research needed to allow the development of evidence-based recommendations for antibiotic-treatment and -prevention of travellers\u2019 diarrhoea were identified.<\/jats:p><jats:p>Conclusions: Increasing worldwide occurrence of antibiotic resistance should alert public health officials of the importance of encouraging local antibiotic stewardship guidelines. Six areas to research are identified in this review to allow the development of evidence-based recommendations for use of antibiotics for treatment and selective prevention of travellers\u2019 diarrhoea. An interdisciplinary ISTM Consensus group will consider the data available and develop current recommendations for therapy and chemoprevention of travellers\u2019 diarrhoea considering groups who would benefit the most from antimicrobials while recognizing the hazards associated with broad use of these drugs. With interim recommendations and ultimately evidence-based recommendations, guidelines can be developed for management of travellers\u2019 diarrhoea considering populations and destinations.<\/jats:p>","DOI":"10.1093\/jtm\/tax040","type":"journal-article","created":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T19:10:10Z","timestamp":1495221010000},"page":"S57-S62","source":"Crossref","is-referenced-by-count":20,"title":["Use of antimicrobial agents for treatment and prevention of travellers\u2019 diarrhoea in the face of enhanced risk of transient fecal carriage of multi-drug resistant enterobacteriaceae: setting the stage for consensus recommendations"],"prefix":"10.1093","volume":"24","author":[{"given":"Herbert L.","family":"DuPont","sequence":"first","affiliation":[{"name":"University of Texas School of Public Health"},{"name":"University of Texas Medical School"},{"name":"Kelsey Research Foundation"},{"name":"Baylor College of Medicine, USA, Houston TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Steffen","sequence":"first","affiliation":[{"name":"Department of Epidemiology, The University of Zurich, Biostatistics and Prevention Institute, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,6,7]]},"reference":[{"key":"2020041602153706000_tax040-B1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-59-5-605","article-title":"The diarrhea of travelers to Mexico. Summary of five-year study","volume":"59","author":"Kean","year":"1963","journal-title":"Ann Intern Med"},{"key":"2020041602153706000_tax040-B2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJM198209303071401","article-title":"Treatment of travelers' diarrhea with trimethoprim\/sulfamethoxazole and with trimethoprim alone","volume":"307","author":"DuPont","year":"1982","journal-title":"N Engl J Med"},{"key":"2020041602153706000_tax040-B3","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1708-8305.2009.00300.x","article-title":"Expert review of the evidence base for self-therapy of travelers\u2019 diarrhea","volume":"16","author":"DuPont","year":"2009","journal-title":"J Travel Med"},{"key":"2020041602153706000_tax040-B4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1708-8305.2008.00299.x","article-title":"Expert review of the evidence base for prevention of travelers\u2019 diarrhea","volume":"16","author":"DuPont","year":"2009","journal-title":"J Travel Med"},{"key":"2020041602153706000_tax040-B5","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1093\/clinids\/8.Supplement_2.S109","article-title":"Travelers\u2019 diarrhea: National Institutes of Health Consensus Development Conference","volume":"8(Suppl 2)","author":"Gorbach","year":"1986","journal-title":"Rev Infect Dis"},{"key":"2020041602153706000_tax040-B6","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2015.20.47.30074","article-title":"International travel and acquisition of multidrug-resistant Enterobacteriaceae: a systematic review","volume":"20","author":"Hassing","year":"2015","journal-title":"Euro Surveill"},{"key":"2020041602153706000_tax040-B7","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s10096-010-1031-y","article-title":"Colonisation with Escherichia coli resistant to \u201ccritically important\u201d antibiotics: a high risk for international travellers","volume":"29","author":"Kennedy","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020041602153706000_tax040-B8","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1186\/1471-2334-14-528","article-title":"High colonization rates of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli in Swiss travellers to South Asia- a prospective observational multicentre cohort study looking at epidemiology, microbiology and risk factors","volume":"14","author":"Kuenzli","year":"2014","journal-title":"BMC Infect Dis"},{"key":"2020041602153706000_tax040-B9","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1708-8305.2011.00548.x","article-title":"Colonization of returning travelers with CTX-M-producing Escherichia coli","volume":"18","author":"Peirano","year":"2011","journal-title":"J Travel Med"},{"key":"2020041602153706000_tax040-B10","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/jac\/dkv441","article-title":"Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in Amsterdam","volume":"71","author":"Reuland","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020041602153706000_tax040-B11","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1128\/AAC.00220-10","article-title":"Foreign travel is a major risk factor for colonization with Escherichia coli producing CTX-M-type extended-spectrum beta-lactamases: a prospective study with Swedish volunteers","volume":"54","author":"Tangden","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2020041602153706000_tax040-B12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/00365540903493715","article-title":"Extended-spectrum beta-lactamase-producing Escherichia coli in patients with travellers\u2019 diarrhoea","volume":"42","author":"Tham","year":"2010","journal-title":"Scand J Infect Dis"},{"key":"2020041602153706000_tax040-B13","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/cid\/ciu957","article-title":"Antimicrobials increase travelers\u2019 risk of colonization by extended-spectrum betalactamase-producing Enterobacteriaceae","volume":"60","author":"Kantele","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020041602153706000_tax040-B14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3201\/eid2201.151272","article-title":"Increased risk for ESBL-producing bacteria from co-administration of loperamide and antimicrobial drugs for travelers\u2019 diarrhea(1)","volume":"22","author":"Kantele","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"2020041602153706000_tax040-B15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.drup.2015.05.001","article-title":"Carbapenemase-producing Enterobacteriaceae in Sweden 2007-2013: Experiences from seven years of systematic surveillance and mandatory reporting","volume":"20","author":"Lofmark","year":"2015","journal-title":"Drug Resist Updat"},{"key":"2020041602153706000_tax040-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkn444","article-title":"Redefining extended-spectrum beta-lactamases: balancing science and clinical need","volume":"63","author":"Giske","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2020041602153706000_tax040-B17","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1093\/cid\/civ333","article-title":"High rate of acquisition but short duration of carriage of multidrug-resistant enterobacteriaceae after travel to the tropics","volume":"61","author":"Ruppe","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020041602153706000_tax040-B18","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1093\/jac\/dkt167","article-title":"Travel-associated faecal colonization with ESBL-producing Enterobacteriaceae: incidence and risk factors","volume":"68","author":"Ostholm-Balkhed","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2020041602153706000_tax040-B19","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/jtm.12211","article-title":"High rate of multidrug-resistant gram-negative bacilli carriage and infection in hospitalized returning travelers: a cross-sectional cohort study","volume":"22","author":"Epelboin","year":"2015","journal-title":"J Travel Med"},{"key":"2020041602153706000_tax040-B20","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1007\/s10096-012-1584-z","article-title":"Prolonged carriage of resistant E. coli by returned travellers: clonality, risk factors and bacterial characteristics","volume":"31","author":"Rogers","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020041602153706000_tax040-B21","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.tmaid.2013.06.004","article-title":"Colonisation with multi-resistant Enterobacteriaceae in hospitalised Danish patients with a history of recent travel: a cross-sectional study","volume":"11","author":"Lausch","year":"2013","journal-title":"Travel Med Infect Dis"},{"key":"2020041602153706000_tax040-B22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ijid.2015.03.006","article-title":"Urinary tract infections due to extended-spectrum beta-lactamase-producing Gram-negative bacteria: identification of risk factors and outcome predictors in an Australian tertiary referral hospital","volume":"34","author":"Osthoff","year":"2015","journal-title":"Int J Infect Dis"},{"key":"2020041602153706000_tax040-B23","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1128\/JCM.01008-08","article-title":"High rate of intestinal colonization with extended-spectrum-beta-lactamase-producing organisms in household contacts of infected community patients","volume":"46","author":"Valverde","year":"2008","journal-title":"J Clin Microbiol"},{"key":"2020041602153706000_tax040-B24","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1086\/657319","article-title":"Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease","volume":"202","author":"Manges","year":"2010","journal-title":"J Infect Dis"},{"key":"2020041602153706000_tax040-B25","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1086\/529380","article-title":"Clostridium difficile-associated diarrhea after antibiotic treatment for traveler's diarrhea","volume":"46","author":"Norman","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020041602153706000_tax040-B26","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10096-003-1084-2","article-title":"Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients","volume":"23","author":"Colodner","year":"2004","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020041602153706000_tax040-B27","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1128\/JCM.06002-11","article-title":"Epidemiology and risk factors of community onset infections caused by extended-spectrum beta-lactamase-producing Escherichia coli strains","volume":"50","author":"Kang","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2020041602153706000_tax040-B28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/jac\/dki166","article-title":"Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community","volume":"56","author":"Pitout","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2020041602153706000_tax040-B29","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3201\/eid2004.131718","article-title":"High rates of antimicrobial drug resistance gene acquisition after international travel, The Netherlands","volume":"20","author":"von Wintersdorff","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"2020041602153706000_tax040-B30","doi-asserted-by":"crossref","first-page":"805","DOI":"10.7326\/0003-4819-142-10-200505170-00005","article-title":"A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers\u2019 diarrhea","volume":"142","author":"DuPont","year":"2005","journal-title":"Ann Intern Med"},{"key":"2020041602153706000_tax040-B31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.13434","article-title":"Review article: the antimicrobial effects of rifaximin on the gut microbiota","volume":"43(Suppl 1)","author":"DuPont","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2020041602153706000_tax040-B32","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ijantimicag.2014.01.026","article-title":"In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK","volume":"43","author":"Hopkins","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2020041602153706000_tax040-B33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/QCO.0b013e3283304eb6","article-title":"Genetics of susceptibility to infection with enteric pathogens","volume":"22","author":"Flores","year":"2009","journal-title":"Curr Opin Infect Dis"},{"key":"2020041602153706000_tax040-B34","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3201\/1108.050103","article-title":"Multidrug-resistant Acinetobacter extremity infections in soldiers","volume":"11","author":"Davis","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"2020041602153706000_tax040-B35","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/jtm.12114","article-title":"Persistent abdominal symptoms in US adults after short-term stay in Mexico","volume":"21","author":"Nair","year":"2014","journal-title":"J Travel Med"},{"key":"2020041602153706000_tax040-B36","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1111\/j.1572-0241.2004.30435.x","article-title":"Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico","volume":"99","author":"Okhuysen","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"2020041602153706000_tax040-B37","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1038\/ajg.2009.302","article-title":"Development and validation of a risk score for post-infectious irritable bowel syndrome","volume":"104","author":"Thabane","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"2020041602153706000_tax040-B38","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0016-5085(19)31771-8","article-title":"Symptomatic treatment of diarrhea with bismuth subsalicylate among students attending a Mexican university","volume":"73","author":"DuPont","year":"1977","journal-title":"Gastroenterology"},{"key":"2020041602153706000_tax040-B39","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/infdis\/157.5.1008","article-title":"Travelers\u2019 diarrhea in West Africa and Mexico: fecal transport systems and liquid bismuth subsalicylate for self-therapy","volume":"157","author":"Steffen","year":"1988","journal-title":"J Infect Dis"},{"key":"2020041602153706000_tax040-B40","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jama.1987.03390100085031","article-title":"Prevention of travelers' diarrhea by the tablet formulation of bismuth subsalicylate","volume":"257","author":"DuPont","year":"1987","journal-title":"Jama"},{"key":"2020041602153706000_tax040-B41","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1001\/jama.1980.03300290019013","article-title":"Prevention of traveler\u2019s diarrhea (emporiatric enteritis). Prophylactic administration of subsalicylate bismuth)","volume":"243","author":"DuPont","year":"1980","journal-title":"Jama"},{"key":"2020041602153706000_tax040-B42","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1093\/clinids\/8.Supplement_2.S151","article-title":"Prevention of travelers\u2019 diarrhea by nonantibiotic drugs","volume":"8(Suppl 2)","author":"Steffen","year":"1986","journal-title":"Rev Infect Dis"},{"key":"2020041602153706000_tax040-B43","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1177\/106002808702100901","article-title":"Bismuth subsalicylate in the treatment and prevention of diarrheal disease","volume":"21","author":"DuPont","year":"1987","journal-title":"Drug Intell Clin Pharm"},{"key":"2020041602153706000_tax040-B44","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/S0016-5085(83)80066-3","article-title":"Double-blind comparison of bismuth subsalicylate and placebo in the prevention and treatment of enterotoxigenic Escherichia coli-induced diarrhea in volunteers","volume":"85","author":"Graham","year":"1983","journal-title":"Gastroenterology"},{"key":"2020041602153706000_tax040-B45","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nature06244","article-title":"The human microbiome project","volume":"449","author":"Turnbaugh","year":"2007","journal-title":"Nature"},{"key":"2020041602153706000_tax040-B46","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1126\/science.1110591","article-title":"Diversity of the human intestinal microbial flora","volume":"308","author":"Eckburg","year":"2005","journal-title":"Science"},{"key":"2020041602153706000_tax040-B47","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/19490976.2015.1019693","article-title":"Characterization of the human gut microbiome during travelers\u2019 diarrhea","volume":"6","author":"Youmans","year":"2015","journal-title":"Gut Microbes"},{"key":"2020041602153706000_tax040-B48","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1099\/mic.0.040618-0","article-title":"Long-term impacts of antibiotic exposure on the human intestinal microbiota","volume":"156","author":"Jernberg","year":"2010","journal-title":"Microbiology"},{"key":"2020041602153706000_tax040-B49","first-page":"1543.","article-title":"Antibiotics and the human gut microbiome: dysbioses and accumulation of resistances","volume":"6","author":"Francino","year":"2015","journal-title":"Front Microbiol"},{"key":"2020041602153706000_tax040-B50","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1093\/cid\/civ177","article-title":"New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics","volume":"60(Suppl 2)","author":"Patel","year":"2015","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jtm\/article-pdf\/24\/suppl_1\/S57\/33046898\/tax040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jtm\/article-pdf\/24\/suppl_1\/S57\/33046898\/tax040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T19:11:31Z","timestamp":1659035491000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/24\/suppl_1\/S57\/3862054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,1]]},"references-count":50,"journal-issue":{"issue":"suppl_1","published-online":{"date-parts":[[2017,6,7]]},"published-print":{"date-parts":[[2017,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/tax040","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"value":"1195-1982","type":"print"},{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,4]]},"published":{"date-parts":[[2017,4,1]]}}}